Over the last decade, there has been a flurry of research on adjuvants for vaccines, and
several novel adjuvants are now in licensed products or in late stage clinical development …

Malaria is a mosquito-borne disease caused by protozoan parasites of the genus
Plasmodium. Despite significant declines in malaria-attributable morbidity and mortality over …

Peptide-based subunit vaccines are of great interest in modern immunotherapy as they are
safe, easy to produce and well defined. However, peptide antigens produce a relatively …

School‐age children have attracted relatively little attention as a group in need of special
measures to protect them against malaria. However, increasing success in lowering the …

Summary Background RTS, S/AS02A is a pre-erythrocytic stage malaria vaccine that
provides partial protection against infection in malaria-naive adult volunteers and …

Malaria is a leading cause of mortality and morbidity globally, and effective vaccines are
urgently needed. Malaria vaccine approaches can be broadly grouped as pre‐erythrocytic …

RTS, S is the most advanced candidate vaccine against human malaria. During its
remarkable journey from conception and design in the early 1980s to the multicenter Phase …

Malaria—a parasite vector-borne disease—is a global health problem, and Plasmodium
falciparum has proven to be the deadliest among Plasmodium spp., which causes malaria in …

The last several years have seen significant progress in the development of vaccines
against malaria. Most recently, proof-of-concept of vaccine-induced protection from malaria …

Worldwide strategies between 2010 and 2017 aimed at controlling malarial parasites
(mainly Plasmodium falciparum) led to a reduction of just 18% regarding disease incidence …